HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Petasites--Zeller: ZE 339.

Abstract
The Swiss company Zeller is developing an extract of the plant Petasites hybridus (butterbur) as an antiallergic agent. Petasites hybridus extracts have been known for some time to have therapeutic properties. Zeller's extract is codenamed ZE 339. In in vitro studies, ZE 339 inhibited cysteinyl-leukotriene synthesis in eosinophils and leukotriene B4 synthesis in neutrophils. In mid-2003, ZE 339 was approved, and launched, in Switzerland as Tesalin for the treatment of seasonal allergic rhinitis as a prescription-only product. Tesalin is available as film-coated tablets. Zeller has stated that hepatotoxicity cannot be totally excluded as a possible adverse reaction to Tesalin.
Authors
JournalDrugs in R&D (Drugs R D) Vol. 4 Issue 6 Pg. 378-9 ( 2003) ISSN: 1174-5886 [Print] New Zealand
PMID14584971 (Publication Type: Journal Article, Review)
Chemical References
  • Anti-Allergic Agents
  • Leukotriene Antagonists
  • Plant Extracts
  • Ze 339
Topics
  • Animals
  • Anti-Allergic Agents (adverse effects, pharmacology)
  • Clinical Trials as Topic
  • Humans
  • Leukotriene Antagonists (adverse effects, pharmacology)
  • Plant Extracts (adverse effects, pharmacology)
  • Rhinitis, Allergic, Seasonal (drug therapy)

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: